Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis
Journal of Cancer Research and Clinical Oncology · 2024
DOI: 10.1007/s00432-024-05741-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Amin Aliabadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Colonic Neoplasms, Apoptosis, Cell Proliferation, Cromolyn Sodium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz Institute for Cancer Research, Shiraz, Iran.
Abstract (Originalsprache)
Purpose
Colon cancer is a prevalent cancer globally, representing approximately 10% of all cancer cases and accounting for 10% of all cancer-related deaths. Therefore, finding new therapeutic methods with high efficiency will be very valuable. Cromolyn ( C ), a common anti-allergic and mast cell membrane stabilizing drug, has recently shown valuable anti-cancer effects in several studies. This study was designed to investigate the anti-cancer activity of cromolyn on colon cancer in vitro and in vivo and to determine values such as selectivity index and survival effect.
Methods
HT-29 (colon cancer) and MCF-10 (normal epithelial) cell lines were treated with C and Doxorubicin (DOX; Positive control). IC50 values and the effects of C and DOX on apoptosis were explored using methyl thiazole diphenyl-tetrazolium bromide (MTT) assay and Annexin V/PI Apoptosis Assay Kit. To investigate in an animal study, colon cancer was subcutaneously induced by CT26 cells (mouse colon cancer) in bulb/c mice. Mice were treated with 0.05 LD50 intraperitoneal every other day for 35 days. After the death of mice, tumor volume, tumor weight, and survival rate were evaluated.
Results
C selectively and significantly suppressed the proliferation of cancer cells in a dose-dependent manner. The IC50 values for the MCF-10 and HT29 cell lines were 7.33 ± 0.78 μM and 2.33 ± 0.6 μM, respectively. Notably, the selective index (SI) highlighted that C displayed greater selectivity in inhibiting cancer cell growth compared to DOX, with SI values of 3.15 and 2.60, respectively. C exhibited higher effectiveness and selectivity in inducing apoptosis in cancer cells compared to DOX, with a significant p-value (61% vs. 52%, P-value ≤ 0.0001). Also, in mice bearing colon cancer, C reduced the tumor volume (6317 ± 1685mm 3 ) and tumor weight (9.8 ± 1.6 g) compared to the negative control group (weight 12.45 ± 0.9 g; volume 7346 ± 1077) but these values were not statistically significant (P ≤ 0.05).
Conclusion
Our study showed that cromolyn is a selective and strong drug in inhibiting the proliferation of colon cancer cells. Based on our results, the efficacy of C in vitro analysis (MTT assays and apoptosis), as well as animal studies is competitive with the FDA-approved drug doxorubicin. C is very promising as a low-complication and good-efficacy drug for cancer drug repositioning. This requires clinical research study designs to comprehensively evaluate its anti-cancer effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. panjeshm@sums.ac.ir.
- Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. erfanin@sums.ac.ir.
- Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. erfanin@sums.ac.ir.
Förderung
- Shiraz University of Medical Sciences, Shiraz, Iran
- Shiraz Institute for Cancer Research, Shiraz, Iran
Zitieren
APA
Aliabadi, A., Haghshenas, M. R., Kiani, R., Panjehshahin, M. R., & Erfani, N. (2024). Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05741-2
Vancouver
Aliabadi A, Haghshenas MR, Kiani R, Panjehshahin MR, Erfani N. Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05741-2
BibTeX
@article{Aliabadi2024,
author = {Aliabadi, Amin and Haghshenas, Mohammad Reza and Kiani, Razie and Panjehshahin, Mohammad Reza and Erfani, Nasrollah},
title = {Promising anticancer activity of cromolyn in colon cancer: in vitro and in vivo analysis},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
doi = {10.1007/s00432-024-05741-2}
}
EUVIMED